Bannerbild German Brest Group

GBG Studien beim ASCO 2019: Ein Erfolg auf ganzer Linie


Auf dem Jahreskongress der amerikanischen Krebsgesellschaft ASCO, der vom 31. Mai bis 4. Juni in Chicago stattfand, konnte die German Breast Group GBG aktuelle Forschungsergebnisse und neue Studienkonzepte vorstellen. In 10 Sitzungen fanden sowohl eigene GBG-Studien Berücksichtigung, als auch Studien, an denen GBG-Forscher maßgeblich beteiligt waren.

#3075: Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.

  • Poster Session Developmental Therapeutics and Tumor Biology (Nonimmuno); Sat, Jun 01, 8:00 AM - 11:00 AM (poster)
  • First author: C. Denkert, Institut für Pathologie Philipps-Universität Marburg, Germany
  • Poster download

#1012: Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.

  • Session: Clinical Science Symposium Targeting Breast Cancer: Breaking the Code; Sat, Jun 01, 3:36 PM - 3:48 PM (oral presentation)
  • First author: IE. Krop, Dana-Farber Cancer Institute, Boston, MA

#509: Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.

  • Poster Discussion Session on Sunday, June 2, 2019, 4:30 PM - 6:00 PM (poster discussion)
  • First author: S. Loibl, GBG Neu-Isenburg, Germany
  • Poster download

#588: Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial.

  • Poster Session Breast Cancer - Local/Regional/Adjuvant; Sun, Jun 02, 8:00 AM - 11:00 AM (poster)
  • First author: B. Seliger, Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
  • Poster download

#573: Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).

  • Poster Session Breast Cancer - Local/Regional/Adjuvant; Sun, Jun 02, 8:00 AM - 11:00 AM (poster)
  • First author: E.Pohl-Rescigno, Center for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
  • Poster download

#TPS605: NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

  • Poster Session: Breast Cancer - Local/Regional/Adjuvant; Sun, Jun 02, 8:00 AM - 11:00 AM (poster)
  • First author: IE. Krop, Dana-Farber Cancer Institute, Boston, MA
  • Poster download

#513: Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

  • Poster Discussion Session on Sunday; June 2, 2019, 4:30 PM - 6:00 PM (poster discussion)
  • First author: A. Schneeweiss, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

#510: Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.

  • Poster Discussion Session on Sunday; June 2, 2019, 8:00 AM - 11:00 AM (poster discussion)
  • First author: O. Metzger, Dana-Farber Cancer Institute, Boston, MA

#506: GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).

  • Session: Oral Abstract Session, Breast Cancer - Local/Regional/Adjuvant; Mon, Jun 03, 11:45 AM - 11:57 AM (oral presentation)
  • First author: PA. Fasching, Department of Gynecology and Obstetrics; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
  • Presentation downlaod


  • 05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial

    The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

    Mehr ...
  • 15.10.2018 GBG Research at ESMO

    Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.

    Mehr ...
  • 11.10.2018 BIG newsletter no 9 is out

    We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.

    Mehr ...
  • 27.09.2018 Paper of the month: models for pCR

    Paper of the month: models for pCR

    A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd